However, this has not been without its challenges, as many COX-2-specific drugs have been withdrawn from the market in recent years due to an association with high blood pressure, thrombosis, and heart attacks, especially in COX-2 inhibitors that impede prostacyclin [44,45]. This evidence concerns the gene PTGS2 and myocardial infarction.